Utility of Ultrasound Imaging for Diagnosis of Focal Liver Lesions: A Radiomics Analysis
Intelligent Diagnosis of Focal Liver Lesions and Thermal Ablation Zone of Liver Cancer Based on Ultrasound Imaging
1 other identifier
observational
10,000
1 country
1
Brief Summary
Ultrasound (US) as first-line imaging technology in detecting focal liver lesions,also plays a crucial role in evaluating image and guiding ablation which is the main treatment for liver lesions. However, the effect of US in diagnosing liver lesions is challenged by several factors including being highly dependent on doctor's experience, low signal-to-noise ratio, low resolution for lesion feature,large error from thermal field evaluation during the process of ablation and so on. Therefore, it is of great significance to construct an intelligent US analysis system depending on the digital information technology. Basing on these problems,the following research will be involved in our project: 1) US database of liver lesions with seamless connection to Picture Archiving and Communication Systems (PACS) will be developed, with the aim to provide standard data for intelligent US analysis. 2) Deep learning model for accurate segmentation, detection and classification of liver lesions on US images will be studied. Then automatic extraction, selection and analysis of liver lesion ultrasound features and the intelligent US diagnosis for liver lesions will be realized. 3) Proposing a clustering model with deep image features, and depicting the similarity measurement of liver cancer, which can be furthered used to link the liver cancer feature to optimal ablation parameters. The intelligent decision-making system for quantifying thermal ablation will be established. 4) Regression algorithm and Generative Adversarial Nets will be developed to extract the image features of liver cancer which will predict risk factors after US-guided thermal ablation.Based on the above researches, it is of great value to establish an intelligent focal liver lesion US diagnosis system involving intelligent diagnosis,personalized ablation strategy and accurate prognosis evaluation, improving the level of accurate diagnosis and treatment of liver lesions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
April 29, 2018
CompletedFirst Posted
Study publicly available on registry
March 12, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2021
CompletedMarch 12, 2019
April 1, 2018
4 years
April 29, 2018
March 11, 2019
Conditions
Outcome Measures
Primary Outcomes (3)
AUC value
Area under the receiver operating characteristic (ROC) curve (AUC)
through study completion, an average of 3 year
specificity
diagnosis specificity of intelligent ultrasound analysis
through study completion, an average of 3 year
sensitivity
diagnosis sensitivity of intelligent ultrasound analysis
through study completion, an average of 3 year
Interventions
therre is no intervention diagnosis or treatment for patients
Eligibility Criteria
patients with focal liver lesions
You may qualify if:
- clear ultrasound imaging of focal liver lesions including malignant liver tumors such as hepatocellular carcinoma, metastatic liver cancer and benigh liver tumors such as hemangioma and focal nodular hyperplasia and so on can be acquired.
- clear ultrasound imaging of liver tissues backgroud without lesions can be acquired.
- disease history and pathological diagnosis of the lesions can be acquired.
You may not qualify if:
- patients unsuitable for ultrasound san
- patients counldn't provide disease history such as hepatitis, alcohol intake and so on
- patients without pathological results
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Related Publications (2)
Du Z, Fan F, Ma J, Liu J, Yan X, Chen X, Dong Y, Wu J, Ding W, Zhao Q, Wang Y, Zhang G, Yu J, Liang P. Development and validation of an ultrasound-based interpretable machine learning model for the classification of </=3 cm hepatocellular carcinoma: a multicentre retrospective diagnostic study. EClinicalMedicine. 2025 Feb 13;81:103098. doi: 10.1016/j.eclinm.2025.103098. eCollection 2025 Mar.
PMID: 40034568DERIVEDYang Y, Cairang Y, Jiang T, Zhou J, Zhang L, Qi B, Ma S, Tang L, Xu D, Bu L, Bu R, Jing X, Wang H, Zhou Z, Zhao C, Luo B, Liu L, Guo J, Nima Y, Hua G, Wa Z, Zhang Y, Zhou G, Jiang W, Wang C, De Y, Yu X, Cheng Z, Han Z, Liu F, Dou J, Feng H, Wu C, Wang R, Hu J, Yang Q, Luo Y, Wu J, Fan H, Liang P, Yu J. Ultrasound identification of hepatic echinococcosis using a deep convolutional neural network model in China: a retrospective, large-scale, multicentre, diagnostic accuracy study. Lancet Digit Health. 2023 Aug;5(8):e503-e514. doi: 10.1016/S2589-7500(23)00091-2.
PMID: 37507196DERIVED
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof
Study Record Dates
First Submitted
April 29, 2018
First Posted
March 12, 2019
Study Start
January 1, 2017
Primary Completion
December 30, 2020
Study Completion
December 30, 2021
Last Updated
March 12, 2019
Record last verified: 2018-04